Rakuten Investment Management Inc. Grows Stake in Pfizer Inc. $PFE

Rakuten Investment Management Inc. raised its stake in Pfizer Inc. (NYSE:PFE) by 773.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 747,946 shares of the biopharmaceutical company’s stock after acquiring an additional 662,360 shares during the period. Rakuten Investment Management Inc.’s holdings in Pfizer were worth $18,699,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Abound Financial LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at $31,000. Bluedoor Private Wealth LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at $333,000. 71 West Capital Partners purchased a new stake in shares of Pfizer during the fourth quarter valued at $274,000. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Pfizer during the fourth quarter valued at $2,507,000. Finally, LFG Wealth Partners LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at $1,438,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on PFE shares. Citigroup increased their price objective on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Guggenheim increased their price objective on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Morgan Stanley increased their price objective on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. HSBC increased their target price on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $30.00 target price on shares of Pfizer in a report on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus price target of $28.82.

Pfizer Stock Down 0.8%

NYSE PFE opened at $26.01 on Tuesday. The stock’s 50-day moving average price is $26.38 and its 200-day moving average price is $26.33. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75. The company has a market capitalization of $148.24 billion, a P/E ratio of 19.86 and a beta of 0.34.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the company earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 12th. Shareholders of record on Friday, May 8th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date was Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s obesity drug berobenatide posted encouraging Phase 2b results, with favorable tolerability and proof-of-concept data that could strengthen the company’s late-stage pipeline. Pfizer Obesity Pipeline Gains Traction As Berobenatide Data Support Valuation
• Positive Sentiment: Pfizer has been upgraded by RBC Capital, reinforcing optimism around the stock’s valuation and income appeal. Pfizer (PFE) Upgraded at RBC Capital. Here is Why
• Positive Sentiment: The CEO said Pfizer could eventually get back to high-single-digit growth, suggesting the business may be better positioned than some investors expect. Here’s When Pfizer’s CEO Says the Company Might Get Back to Generating High-Single-Digit Growth
• Neutral Sentiment: Multiple research and analyst roundups focused on Pfizer’s growth drivers, challenges, and recent stock performance, keeping the stock in the spotlight but without a major new catalyst. Top Research Reports for Pfizer & Newmont Corp.
• Neutral Sentiment: Pfizer was among the most searched stocks on Zacks, reflecting investor curiosity around what comes next for the name. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Coverage on Pfizer’s discounted valuation weighed the downside from fading COVID revenue and patent cliffs against upside from oncology, new products, and pipeline execution. Is Pfizer’s Discounted Valuation a Buying Opportunity or a Value Trap?

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.